RT Journal Article
SR Electronic
T1 Emergence of a Novel Reassortant Clade 2.3.2.1c Avian Influenza A/H5N1 Virus Associated with Human Cases in Cambodia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.04.24313747
DO 10.1101/2024.11.04.24313747
A1 Siegers, Jurre Y.
A1 Xie, Ruopeng
A1 Byrne, Alexander M.P.
A1 Edwards, Kimberly M.
A1 Hu, Shu
A1 Yann, Sokhoun
A1 Sin, Sarath
A1 Tok, Songha
A1 Chea, Kimlay
A1 Horm, Sreyviseth
A1 Rith, Chenthearath
A1 Keo, Seangmai
A1 Pum, Leakhena
A1 Duong, Veasna
A1 Auerswald, Heidi
A1 Phou, Yisuong
A1 Kol, Sonita
A1 Spiegel, Andre
A1 Harvey, Ruth
A1 Tum, Sothyra
A1 Sorn, San
A1 Seng, Bunnary
A1 Sengdoeurn, Yi
A1 Darapheak, Chau
A1 Savuth, Chin
A1 Hak, Makara
A1 Ieng, Vanra
A1 Patel, Sarika
A1 Di, Han
A1 Davis, Charles Todd
A1 Finlay, Alyssa
A1 Sar, Borann
A1 Thielen, Peter
A1 Claes, Filip F.
A1 Lewis, Nicola S.
A1 Sovann, Ly
A1 Dhanasekaran, Vijaykrishna
A1 Karlsson, Erik A.
YR 2024
UL http://medrxiv.org/content/early/2024/11/05/2024.11.04.24313747.abstract
AB After nearly a decade without reported human A/H5N1 infections, Cambodia faced a sudden resurgence with 16 cases between February 2023 and August 2024, all caused by A/H5 clade 2.3.2.1c viruses. Fourteen cases involved a novel reassortant A/H5N1 virus with gene segments from both clade 2.3.2.1c and clade 2.3.4.4b viruses. The emergence of this novel genotype underscores the persistent and ongoing threat of avian influenza in Southeast Asia. This study details the timeline and genomic epidemiology of these infections and related poultry outbreaks in Cambodia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAvian influenza work in the Virology Unit at Institut Pasteur du Cambodge was funded, in part, by the Food and Agriculture Organization of the United Nations Global Health Security Program (funded by USAID), the World Health Organization, and the Bill and Melinda Gates Foundation. H.A. is supported, in part, by the German Centre for International Migration and Development. PMT was supported by Johns Hopkins APL internal research and development. R.X., K.M.E., S.H. and V.D. were funded in part by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, under Contract No. 75N93021C00016. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All H5 sequences and information (e.g. collection date, location) included in this analysis were obtained as part of human H5 case testing and One Health response as described below. All data included in this study is available in the public record. All patient samples were de-identified and no other individual-specific information was used in this study. Analyses in this study have been approved by the Cambodian National Ethics Committee for Health Research (#365NECHR/2024).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis study generated a total of 83 gene segments obtained from 12 human A/H5N1 and 329 segments from 51 avian A/H5N1 influenza A viruses were deposited in GISAID. Accession numbers can be found in Supplemental Table 2.